Drug Pipeline Progress: Clinical trial results for I-Mab's drug candidates significantly impact investor sentiment. Positive data boosts the stock, while failures can cause declines.

Regulatory Approvals: Receiving approval from regulatory bodies like the FDA or EMA for its drugs is a major catalyst, driving stock prices higher.

Partnerships and Licensing: Forming collaborations or licensing agreements with larger pharmaceutical companies often leads to upfront payments and future royalties, positively influencing the stock.

Financial Performance: I-Mab's revenue, expenses, and cash position affect investor confidence. Strong financials support the stock price.

Market Conditions: Broader market trends in the biotechnology sector and overall economic conditions can influence I-Mab's stock performance.

Competition: The presence of competing drugs or companies in the same therapeutic areas can impact I-Mab's market potential and stock valuation.

Management Team: The experience and reputation of I-Mab's leadership team play a role in investor trust and the company's ability to execute its strategy.

Intellectual Property: Strength and scope of I-Mab's patents protecting its drug candidates are crucial for long-term value and investor appeal.